Nucleic Acid Pathogen Testing - Cigna

← Back to document page

Medical Coverage Policy Effective Date ........................................ ..... 9/15/2021. Next Review 1/15/2022. Coverage Policy Number .................................. 0530. Nucleic acid Pathogen Testing Table of Contents Related Coverage Resources Overview ........................................ ...................... 1 Preventive Care Services Coverage General Background ........................................ ....3. Medicare Coverage Determinations ....................8. Coding/Billing Information ....................................9. References ........................................ ................36. INSTRUCTIONS FOR USE. The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients.

A nucleic acid test analyzes tiny amounts of DNA or RNA in a sample of blood, tissue or body fluid. Because the amount of genetic material is very small the test may include a step where the DNA or RNA of the microorganism is amplified, or increased. This type of nucleic acid pathogen test is known as a nucleic acid amplification test or NAAT.

  Pathogens, Testing, Acid, Nucleic acid, Nucleic, Nucleic acid pathogen testing, Nucleic acid pathogen